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REVERSAL OF REFRACTORY HYPOTENSION WITH SINGLE-DOSE METHYLENE BLUE AFTER 
CORONARY ARTERY BYPASS SURGERY
P. Yiu, FRCS,a J. Robin, MRCP,b and C. W. Pattison, FRCS,a London, United Kingdom
Low systemic vascular resistance (SVR) requiring vaso-
constrictor therapy is a recognized complication of car-
diopulmonary bypass. We present here a case in which nor-
epinephrine therapy had failed and alternative strategy with a
guanylate cyclase inhibitor, methylene blue, was instituted,
resulting in a rapid, permanent restoration of hemodynamic
stability.
Clinical summary. A 72-year-old man with 3-vessel dis-
ease and moderate left ventricular function was admitted for
coronary artery bypass surgery. Coronary risk factors includ-
ed hypercholesterolemia, hypertension, prior smoking, and a
family history of heart disease. He was on a program of
amlodipine, atenolol, enalapril, simvastatin, and aspirin.
Medical history included a cerebrovascular accident. His
blood pressure was 150/90 mm Hg and he had atrial fibrilla-
tion with a pulse rate of 60 beats/min. Baseline blood results
were normal apart from a borderline serum creatinine value
of 105 m mol/L.
Coronary artery bypass grafting was performed under nor-
mothermic conditions with intermittent crossclamp fibrilla-
tion. The operation was uneventful and total bypass time was
67 minutes. He was transferred to the intensive care unit
receiving intravenous glyceryl trinitrate (2 mL/h) and cardiac
dopamine (10.9 m g/kg per minute). Four hours after the oper-
ation, his blood pressure progressively sagged. The central
venous pressure was 10 mm Hg and the hemoglobin level
was 8.9 g/dL after a total of 2.5 L of colloid and 1 unit of
blood. Blood loss was negligible and oxygen tension was
13.5 kPa on an inspired oxygen fraction of 0.4. The electro-
cardiogram showed no ischemic changes. The dopamine
infusion was reduced to a renal dose, and an epinephrine
infusion was commenced at 5 m g/min, but this needed to be
increased to 13 m g/min 4 hours later (Fig 1). Esophageal
Doppler monitoring showed a high cardiac output of 8.4
L/min with a low calculated SVR of 455 dynes · sec/cm5. As
a result, norepinephrine was started and epinephrine was
weaned. Over the course of 9 hours the patient’s requirement
for norepinephrine to maintain a systolic pressure above 90
mm Hg escalated to 45 m g/min. His cardiac output was 9.2
L/min and the SVR was still low at 550 dynes · sec/cm5.
Methylene blue (2 mg/kg) was given intravenously over 20
minutes with an immediate rise in blood pressure. Within the
hour, the norepinephrine infusion was discontinued. His
hemodynamic state remained stable on epinephrine alone (10
m g/min). No additional methylene blue was required and he
was weaned off all inotropic support the following day.
He remained apyrexial with a normal white cell count. All
microbial cultures were negative. Apart from routine prophy-
lactic antibiotics, he received no other antimicrobial therapy.
The postoperative amylase value was within normal limits.
His postoperative recovery was delayed by acute nonolig-
uric renal dysfunction with a creatinine peak of 358 m mol/L
and a popliteal deep vein thrombosis. Both complications
resolved with conservative management.
Discussion. The mechanism behind low SVR after car-
diopulmonary bypass is poorly understood but is related to
activation of an inflammatory response.1 Preoperative use of
angiotensin-converting enzyme inhibitors is a possible pre-
disposing factor.2 Some patients with significant low SVR
require vasoconstrictor therapy, typically norepinephrine.
Our patient was norepinephrine resistant and urgently needed
an alternative approach. We found that methylene blue (2
mg/kg) was remarkably effective, and a single dose was suf-
ficient to permanently restore hemodynamic stability. The
clinical response was correlated with normalization of the
SVR and cardiac output.
Published data to date have seen methylene blue (a guany-
late cyclase inhibitor) being used primarily in septic shock.
Endotoxemia induces substantial nitric oxide release, which
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stimulates guanylate cyclase in vascular smooth muscle cells,
resulting in loss of vasomotor tone.3,4 Interestingly, there was
no evidence of sepsis in this patient. The sustained effect of
the single-dose treatment would also support a pro-inflam-
matory insult. Thus the favorable response to methylene blue
suggests that abnormal activation of the nitric oxide pathway
may play a significant role in the low SVR syndrome after
cardiopulmonary bypass. Previous attempts to identify an
increase in nitric oxide release after bypass have failed to find
a rise in serum or urine nitrate/nitrite levels (stable break-
down products of nitric oxide) compared with prebypass lev-
els.5 However, determination of nitric oxide activity using
nitrate/nitrite assay alone can be unreliable. It is also possible
to hypothesize that proinflammatory mediators arising from
cardiopulmonary bypass do not act by stimulating nitric oxide
release but through activation of the final common pathway of
nitric oxide (ie, guanylate cyclase), or else they sensitize vas-
cular smooth muscle cells to the action of nitric oxide.
Conclusions. A single dose of methylene blue successfully
reversed refractory hypotension after cardiopulmonary
bypass in nonsepsis. Activation of guanylate cyclase in vas-
cular smooth muscle may play a key role in the postpump low
SVR syndrome and warrants further studies.
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Fig 1. Diagram illustrating the patient’s inotropic requirements after coronary artery bypass surgery. Hemo-
dynamic indices are also shown. CO, Cardiac output; SVR, systemic vascular resistance.
